NewsPoint of Care Decision Support will be running software and patient engagement mobile application demonstrations at booth #18 during the AC National Conference on Thursday, April 23 and Friday, April 24.
Meeting the key recommendations of The Joint Commission, CMS and the Anticoagulation EHR Task Force, PCDS AC is positioned to be the leading AC therapy decision support tool now and well into the future. Healthcare professionals find the software to be especially valuable in light of new TSOAC drugs coming onto the market, changing AC therapy protocols, and more stringent regulatory guidelines.
Anticoagulation Coalition Electronic Health Record Task Force provides List of EHR features for the delivery of optimized anticoagulation therapy.
Allscripts has certified Point of Care AC for its anticoagulation solution. Point of Care AC introduces a real-time AC application optimizing safety and therapy, and transform evidence-based guidelines into robust, intelligent tools for tracking and evaluating real-time patient therapy protocols and drug reaction history.
More structured anticoagulation management and stewardship programs are needed for nursing home clients. From 2011 to 2014, at least 165 nursing home residents were hospitalized or died after errors involving Coumadin or its generic version, Warfarin, a ProPublica analysis of government inspection reports shows. Studies suggest there are thousands more injuries every year that are never investigated by the government.
The BRIDGE trial is a 5-year National Institutes of Health-sponsored randomized trial to determine whether bridging anticoagulation is needed in patients with atrial fibrillation who are receiving warfarin and need temporary interruption in order to undergo an elective surgery or procedure. The BRIDGE trial, sponsored by the National Institutes of Health, was designed to determine whether bridging anticoagulation is needed in patients with atrial fibrillation who are receiving warfarin and need temporary interruption in order to undergo an elective surgery or procedure.
“[Oral anticoagulants] should be considered for AF patients with one additional stroke risk factor given their high risk of ischemic stroke,” the researchers wrote. “Future studies should attempt to define the net clinical benefit of anticoagulation, balancing the prevention of both thromboembolism and major bleeding, for patients with AF who have one stroke risk factor in addition to sex.” In a related editorial, Hugh Calkins, MD, from the department of cardiology at Johns Hopkins Hospital, said the findings are “striking” and offer new information that supports recommending anticoagulation for all patients with AF except those at very low risk for stroke. However, he wrote, these results alone are not sufficient to warrant an update to current guidelines. “Considering the safety and efficacy of antithrombotic therapy, it seems clear that we should think long and hard before recommending that patients with a CHA2DS2-VASc score of 1 not receive anticoagulant therapy,” Calkins wrote.
More than 70 physicians responded to the survey, which asked them to pick three important cardiology issues or developments that they felt patients should know more about. They selected from 16 topics, including insurance challenges, new treatments for varicose veins, energy drinks, and the pluses and minuses of aspirin therapy. Among the top issues was the "epidemic" of atrial fibrillation, the irregular, often rapid heart rate that can lead to blood clots, heart failure, and stroke.
The healthcare industry needs to catch up with other industries in fully leveraging information technology to drive innovation and advancements in care delivery.
Canadians don't have adequate access to a blood-thinning agent proven to prevent strokes because of the way our health-care reimbursement policies work, doctors say.
Pharmacy quality improvement experts at IPRO have created and field tested a unique audit tool aimed at reducing anticoagulant-related adverse drug events (ADEs) during care transitions. National estimates suggest that ADEs account for 700,000 emergency department visits and 120,000 hospitalizations annually, and The Department of Health and Human Services' recently released National Action Plan for Adverse Drug Event Prevention identifies anticoagulant medications as a major contributor to preventable ADEs and calls for system improvements to protect patients prescribed anticoagulants.
Data from nearly 12,500 patients enrolled in the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF), an innovative, independent academic research initiative, have illustrated that stroke prevention strategies for atrial fibrillation (AF) patients remain sub-optimal despite the transition to a new era of anticoagulation featuring non-vitamin K antagonist oral anticoagulant (NOAC) therapies. The findings, presented this week at ESC Congress 2014, show that treatment patterns in everyday clinical practice are not consistent with evidence-based guidelines, and that inappropriate use and under-use of anticoagulant therapy is associated with worse outcomes for patients
When asthma is poorly managed, its adverse impact is felt community-wide, in increased health costs, lost school days and work time, poor quality of life, increased illness, and death. According the to the Centers for Disease Control and Prevention (CDC), 18.7 million adults and nearly 7 million children had asthma in 2010, a 15% rise since 2001., Asthma is responsible for 1.8 million emergency department (ED) visits, and close to 14.2 million outpatient visits a year.